Overview
- The disposal covered roughly a 1.5% stake and was executed as a block trade arranged by JPMorgan Chase.
- Shares were offered at $108 to $111.70 per ADR, representing up to a 3.3% discount to the prior close.
- BioNTech stock fell between about 4% and 6% intraday as investors digested the change in shareholder base.
- Pfizer could receive roughly $508 million if the sale priced at the top of the indicated range, according to published calculations.
- BioNTech recently lifted 2025 revenue guidance to €2.6–2.8 billion after a large payment from Bristol Myers Squibb and continues to advance its oncology programs.